Clinical trials: Drug Survival
Hepatocellular Carcinoma
Synergistic Treatment for Hepatocellular Carcinoma (HCC) Using Transcatheter Arterial Chemoembolization (TACE) With Anti-hepatitis B Virus (Anti-HBV) Therapy
The purpose of this study is to elucidate the influence of anti-hepatitis B virus therapy on safety and survival of HCC patient after transcatheter arterial chemoembolization.
- Trial name
- TACEHBV (NCT01102335)
- Testing
- Transcatheter arterial chemoembolization (TACE), Telbivudine
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Fudan University
Pediatric Cancer
Food is Medicine in Survivorship: Examining the Feasibility and Impact of a Scalable Food Delivery and Culinary Medicine Program (FoodiiS) Among Pediatric Cancer Survivors and Their Families
The goal of this research study is to learn if the FoodiiS-Kids intervention is useful to parents and guardians of pediatric cancer survivors.
- Trial name
- NCT07218328
- Testing
- FoodiiS plus Culinary Essentials Food Delivery, Culinary Essentials Food Delivery Only, Waitlist control
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Metastatic Colorectal Cancer
Assessment of Clinical Practice Administration of Chemotherapy and Anti-angiogenic Agent (Bevacizumab) in Colorectal Cancer
Investigators propose to assess, retrospectively (from 1/7/2009) and prospectively (up to 31/12/2013,) the safety and tolerability profile (number of participants with adverse events) of standard chemotherapy and anti-angiogenic…
- Trial name
- NCT01811108
- Where
- 6 sites in Greece
- Volunteers
- 670 people
- Sponsor
- Hellenic Oncology Research Group
Follicular Lymphoma, Relapsed/Refractory Follicular Lymphoma
Towards Personalized Medicine for Refractory/Relapsed Follicular Lymphoma Patients: the Cantera/Lupiae Registry
The optimal treatment strategy in patients with early progressive disease is not well known. In recent years, novel insights into the biology of Follicular Lymphoma (FL), and especially the role of the microenvironment, have…
- Trial name
- LUPIAE (NCT04587388)
- Where
- 11 sites in Croatia, Italy and 4 more
- Volunteers
- 500 people
- Sponsor
- European Hematology Association - Lymphoma Group
Cutaneous Adverse
Association Between Drug-related Cutaneous Adverse Events and Progression Free Survival in Patients Treated with Enfortumab Vedotin
Enfortumab vedotin (EV) is an antibody-drug conjugate (ADC) targeting nectin-4. In patients with metastatic urothelial carcinoma, EV in combination with pembrolizumab (anti-PD1) provides significantly better progression-free and…
- Trial name
- SURVSKINTOX-EV (NCT06682845)
- Testing
- Collection of data in patients' medical files
- Where
- France
- Volunteers
- 22 people
- Sponsor
- Hospices Civils de Lyon